NCT02630693 2026-04-13
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
Duke University
Dana-Farber Cancer Institute
Dartmouth-Hitchcock Medical Center
City of Hope Medical Center
MedSIR
University of Nebraska
Hoffmann-La Roche
Syndax Pharmaceuticals
Hoffmann-La Roche
MedImmune LLC
Evgen Pharma
Fudan University
National Cancer Institute (NCI)